Percutaneous Renal Denervation (RDN), is an Innovative Strategy in the Control of Refractory Blood Pressure. A Case Report.
Journal of Internal Medicine and Health Affairs · 2023
DOI: 10.58489/2836-2411/018 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Internal Medicine and Health Affairs, 2023. Verfasst von Hernando Viloria Sanchez und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Arterial hypertension (HBP) is a heterogeneous diseasecharacterized by havinga high degree of morbimortality in patients who suffer from it. Clinically it is diagnosedby taking blood pressure (BP) 1, when a value equal to or higherthan 130/80 mmHg is obtained.Among its classification there is "Refractory Arterial Hypertension" 4-5 which has a low incidence but with a high cardiovascular risk and costs to the health system. Given its high impact, minimally invasive strategies have been created that have had a significant effect in reducing blood pressure levels; this procedure is calledPercutaneous Renal Denervation (RDN) 6-7.
Zitieren
APA
Sanchez, H. V., Badel, A., González, J. S., Barros, G., & Julio, L. M. (2023). Percutaneous Renal Denervation (RDN), is an Innovative Strategy in the Control of Refractory Blood Pressure. A Case Report. Journal of Internal Medicine and Health Affairs. https://doi.org/10.58489/2836-2411/018
Vancouver
Sanchez HV, Badel A, González JS, Barros G, Julio LM. Percutaneous Renal Denervation (RDN), is an Innovative Strategy in the Control of Refractory Blood Pressure. A Case Report. Journal of Internal Medicine and Health Affairs. 2023. doi:10.58489/2836-2411/018
BibTeX
@article{Sanchez2023,
author = {Sanchez, Hernando Viloria and Badel, Aníbal and González, Juan S. and Barros, Guillermo and Julio, Luis Miguel},
title = {Percutaneous Renal Denervation (RDN), is an Innovative Strategy in the Control of Refractory Blood Pressure. A Case Report},
journal = {Journal of Internal Medicine and Health Affairs},
year = {2023},
doi = {10.58489/2836-2411/018}
}
EUVIMED